Day One Biopharmaceuticals
2000 Sierra Point Parkway
Suite 501
Brisbane
CA
94005
United States
Tel: 1-650-484-0899
Website: https://dayonebio.com/
Email: info@dayonebio.com
About Day One Biopharmaceuticals
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.
49 articles with Day One Biopharmaceuticals
-
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
3/6/2023
Day One Biopharmaceuticals announced its fourth quarter and full year 2022 financial results and highlighted recent corporate achievements.
-
Day One to Participate in the Cowen 43rd Annual Health Care Conference
2/27/2023
Day One Biopharmaceuticals announced management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7 at 9:10 a.m. ET.
-
Day One Biopharmaceutical reported positive topline data from a Phase II trial in pediatric low-grade glioma, confirming earlier results.
-
Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
1/8/2023
Day One Biopharmaceuticals announced positive topline results from the ongoing, open-label, pivotal Phase 2 FIREFLY-1 trial evaluating the investigational agent, tovorafenib, as a monotherapy in recurrent or progressive pediatric low-grade glioma.
-
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
12/20/2022
Day One Biopharmaceuticals today announced that Dr. Jeremy Bender, chief executive officer, will present during the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9 at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time.
-
Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
11/17/2022
Day One Biopharmaceuticals today announced that management will participate in a fireside chat at the Piper Sandler 34 th Annual Healthcare Conference on Tuesday, November 29, 2022 at 11:00 a.m. EST.
-
Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting
11/11/2022
Day One Biopharmaceuticals today announced two upcoming presentations at the Society for Neuro-Oncology (SNO) annual meeting, being held from November 16-20, 2022 in Tampa, FL.
-
Day One Reports Third Quarter 2022 Financial Results and Corporate Progress
11/7/2022
Day One Biopharmaceuticals announced financial results for the third quarter of 2022 and highlighted recent corporate achievements.
-
Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)
10/17/2022
Day One Biopharmaceuticals (Nasdaq: DAWN) today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program (CTEP) to expand therapeutic research opportunities using tovorafenib (DAY101).
-
September 24 is World Cancer Research Day, and September is Childhood Cancer Awareness Month. BioSpace spoke with leaders from three companies tackling pediatric glioma.
-
In a recent BioSpace poll, more than half of employers indicated they planned to continue recruiting employees remotely. We highlight just some of those jobs here.
-
Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care
9/21/2022
Foundation Medicine, Inc. and Day One Biopharmaceuticals today announced a collaboration to develop FoundationOne®CDx as a companion diagnostic for Day One’s lead investigational therapy, tovorafenib (DAY101).
-
Day One Appoints Garry Nicholson as Chairman of the Board of Directors
9/12/2022
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced the appointment of Garry Nicholson as chairman of its board of directors.
-
Day One Biopharmaceuticals aims to provide a business solution to a moral problem: the inequity in pediatric oncology drug development.
-
Day One Reports Second Quarter 2022 Financial Results and Corporate Progress
8/4/2022
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced financial results for the second quarter of 2022 and highlighted recent corporate achievements.
-
Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
8/2/2022
Day One Biopharmaceuticals announced that management will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Virtual Conference.
-
Day One Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
6/21/2022
Day One Biopharmaceuticals, Inc. announced the closing on June 17, 2022 of its previously announced upsized underwritten public offering of 11,500,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase 1,500,000 additional shares, at a public offering price of $15.00 per share.
-
Day One Announces Pricing of Upsized Public Offering of Common Stock - June 15, 2022
6/15/2022
Day One Biopharmaceuticals, Inc. announced the pricing of its upsized underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share.
-
Day One Biopharmaceuticals announced positive early data assessing tovorafenib as a once-a-week treatment in people aged six months to 25 years with relapsed or progressive pediatric low-grade glioma.
-
Day One Announces Proposed Public Offering of Common Stock
6/14/2022
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock.